Tibotec to Use Inpharmatica's Chematica Platform
Inpharmatica said last week that Tibotec Pharmaceuticals, a subsidiary of Johnson & Johnson, will use components of its Chematica software platform for its research in HIV research.
Tibotec will use Inpharmatica's StarLite and DrugStore databases to identify molecular targets, screening assays and alternative indications for bioactive compounds, Inpharmatica said.
Defniniens to Open US Subsidiary
Image informatics firm Definiens of Munich, Germany, said last week that it has formed a wholly owned US subsidiary, Definiens Inc., that will have offices in Boston and Boulder, Colo.
The company "is experiencing significant growth in the US" for its software, said Thomas Heydler, Definiens' CEO, in a statement.
The company said that it is adding staff to its US and European offices "in order to support the growing demand for the new products and solutions."
Ryoka to Distribute Partek Software in Japan
Partek said last week that it has signed an agreement with Ryoka Systems under which Ryoka will act as a "premier" distributor for Partek's software in Japan.
Ryoka will provide sales, marketing, and customer support for four of Partek's statistics and data-visualization software products: Partek Discovery Suite, Partek Genomics Solution, Partek QSAR, and Partek Screener's Solution.
Geisinger Joins Penn Cancer Alliance Bioinformatics Consortium
Geisinger Health System said last week that it has joined the Pennsylvania Cancer Alliance Bioinformatics Consortium.
Geisinger patients will now be able to donate leftover tissues for biopsies to the Geisinger Biospecimen Bank. Geisinger researchers will analyze the tissue, and the results will be added to a state-wide data bank open to any consortium researcher.
Other participants in the consortium include the University of Pittsburgh Cancer Institute, Thomas Jefferson University's Kimmel Cancer Center, Fox Chase Cancer Center, University of Pennsylvania's Abramson Cancer Center, the Wistar Institute, Drexel University, Penn State Cancer Institute, and the Windber Research Institute.